Human Respiratory Syncytial Virus Treatment Market Size

Human Respiratory Syncytial Virus Treatment Market Analysis

The human respiratory syncytial virus (RSV) treatment market is expected to register a CAGR of 10% during the forecast period.

COVID-19 had a notable impact on the human respiratory syncytial virus treatment market. The viral interference can alter the pattern and dynamics of syncytial virus infection. For instance, as per the article published in December 2021 in PubMed, the COVID-19 pandemic drastically changed the epidemiology of other viral respiratory infections including RSV in both children and adults. As per the same source, the rhinovirus could compete with other respiratory viruses and change the epidemic dynamics. Thus, during the pandemic, the delayed onset of the infection, as well as the limited number of cases reported, could be attributed to viral interference. However, as the restrictions are eased, the human respiratory syncytial virus treatment market is expected to witness growth in the coming years due to the rise in the prevalence of respiratory syncytial virus and the increase in technological advances in treatment.

Factors such as the rise in the prevalence of RSV and the increase in government support and funding for the development of RSV treatment are expected to drive market growth. For instance, as per the article published in November 2022 in MedRxiv, there were significant racial and ethnic disparities in the peak RSV infection rate during 2010-2021 and the disparities were further exacerbated in 2022 with a peak incidence rate in black and Hispanic children 2-3 times that in white children. Among RSV-infected children in 2022, 19.2% had prior documented COVID-19 infection, significantly higher than the 9.7% among uninfected children, suggesting that prior COVID-19 could be a risk factor for RSV infection or that there are common risk factors for both viral infections. Furthermore, as per the CDC's October 2022 update, in the 2022-2023 season, the overall rate of RSV-associated hospitalization was 43.4 per 100,000 people. Thus, such a rise in RSV infections is likely to increase the demand for proper treatment and thereby drive market growth.

Moreover, the increase in research and development and pipeline assets for RSV treatment by the key players are expected to promote market growth over the forecast period. For instance, in October 2022, GSK's older adult respiratory syncytial virus (RSV) vaccine candidate showed a 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in the pivotal trial. The data presented at IDWeek 2022 showed overall vaccine efficacy against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with a favorable safety profile.

Hence, a rise in RSV infection and an increase in pipeline assets by the key players are expected to increase the growth of the studied market over the forecast period. However, less availability of safe and effective antiviral drugs can hinder the market growth over the study period.